創美藥業(02289.HK)內資股股東轉讓共2905萬股內資股股份予江中醫商
格隆匯1月6日丨創美藥業(02289.HK)公吿,公司董事會已獲知悉,於2022年1月6日,內資股股東遊澤燕、吳濱華、劉吉貴及吳玩平(合稱內資股股東)作為賣方與江西江中醫藥商業運營有限責任公司簽訂股份轉讓協議,據此,內資股股東將其持有的公司共2905萬股的內資股股份(佔本公吿日期公司已發行總股本的26.90%)轉讓給江中醫商,價格為每股6.22元人民幣,總代價為1.81億元人民幣。
本次股份轉讓已於2022年1月6日在中國證券登記結算有限責任公司深圳分公司辦理過户手續並已取得中國證券登記結算有限責任公司深圳分公司出具的《過户登記確認書》。
江中醫商是一家江西省屬國有控股的混合所有制企業,其依託國有企業的政策資源與品牌優勢,以構建為全國縣鄉市場單體藥店、中小連鎖以及診所(非招標市場)提供專業化解決方案的純銷型醫藥商業平台為切入點,全面拓展醫藥生產、現代智能物流、第三方委託配送、“互聯網+金融”以及“互聯網+零售”等戰略業務,致力於打造一個全渠道、全品類、全產業鏈以及全國市場佈局的現代醫藥產業平台。
江中醫商看好本公司未來的發展,收購內資股亦表明其對公司的業務、經營和持續增長的信心。轉讓內資股予江中醫商將可能為公司引入新的業務發展資源和市場影響力,進一步強化公司的軟實力和競爭力,帶動公司發展。內資股轉讓完成後,江中醫商將擁有公吿日期本公司已發行股本約26.90%的權益,並將成為公司主要股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.